Aravive
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3730 Kirby Dr Ste 1200, Houston, Texas, ...Phone Number
(650) 963-8580Website
www.aravive.comRevenue
$8.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravives lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth.Explore more
Aravive Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aravive your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Aravive had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Aravive
Check out if Aravive is spiking on competitors!
Product Launch: Get notified when Aravive launches new products
Website visits: Recent activity has been detected on your website
Aravive, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Aravive has new funding data
Earning: See what the market has to say on Aravive recently announced quarterly report
Check if Aravive has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Aravive
Find more new buyers
Compare Similar Companies to Aravive
Compare insights from companies similar to Aravive, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aravive is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aravive is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aravive.
Aravive financials insights
Gather financial insights about Aravive, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$126M
2022
Stock Offering
$10M
Aravive Tech Stack
A closer look at the technologies used by Aravive
See more technologies
Most Recent Scoops
Open Position
Open Position
Left Company
Executive Move
Award
New Hire
Executive Move
Aravive News & Media
Aravive To Participate in the Jefferies Global Healthcare Conference
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. The poster presentation will highlight uAravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a registrational Phase 3 trial design for batiraxcept in clear cell renal cell carcinoma (ccRCC) at an End-of-Phase 2 (EOP2) meeting.Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported first quarter 2023 financial results and provided corporate updates.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Aravive
Sign Up For FreeTo access detailed company insights
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravives lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth.... Read More
